Blockbuster Patent Expiries Sparking Korean Generic War
This article was originally published in PharmAsia News
Executive Summary
With patents for a series of global blockbuster drugs expiring this year, South Korean pharma firms are fiercely competing to grab bigger pieces of the domestic generic market. Amid an ongoing patent invalidation suit concerning BMS’s Baraclude, Dong-A ST has been banned from producing and selling its generic version until the patent expires, while the Korean pharma association has warned its members against illegal rebates amid intensifying generic competition.